Arvinas Revenue and Competitors
Estimated Revenue & Valuation
- Arvinas's estimated annual revenue is currently $22.6M per year.
- Arvinas received $55.0M in venture funding in April 2018.
- Arvinas's estimated revenue per employee is $51,458
- Arvinas's total funding is $100M.
- Arvinas's current valuation is $3.6B. (January 2022)
Employee Data
- Arvinas has 439 Employees.
- Arvinas grew their employee count by -2% last year.
Arvinas's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | Executive Assistant To President & CEO | Reveal Email/Phone |
3 | Chairperson, CEO, and President | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | CFO, Treasurer, and Principal Financial Officer | Reveal Email/Phone |
6 | VP & Chief Accounting Officer | Reveal Email/Phone |
7 | VP Pharmacovigilance | Reveal Email/Phone |
8 | COO and Sr VP, Clinical Development | Reveal Email/Phone |
9 | VP, Estrogen Receptor Global Asset Lead | Reveal Email/Phone |
10 | SVP Corporate & Business Development | Reveal Email/Phone |
Arvinas Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.2M | 1 | 0% | N/A | N/A |
#2 | $4.3M | 17 | -26% | N/A | N/A |
#3 | $9.8M | 66 | -11% | N/A | N/A |
#4 | $1.4M | 9 | 350% | N/A | N/A |
#5 | $16.6M | 107 | -23% | N/A | N/A |
#6 | $4.5M | 29 | -22% | N/A | N/A |
#7 | $1.7M | 11 | 57% | N/A | N/A |
#8 | $2.3M | 15 | 25% | N/A | N/A |
#9 | $0.3M | 3 | 0% | N/A | N/A |
#10 | $4M | 19 | -10% | N/A | N/A |
What Is Arvinas?
Arvinas is a pharmaceutical company focused on developing new small molecules - known as PROTACs (PROteolysis TArgeting Chimeras) - aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting undruggable as well as druggable elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets. For more information, visit www.arvinas.com.
keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals
$100M
Total Funding
439
Number of Employees
$22.6M
Revenue (est)
-2%
Employee Growth %
$3.6B
Valuation
N/A
Accelerator
Arvinas News
On average, analysts expect that Arvinas will report full year sales of $131.08 million for the current financial year, with estimates ranging...
Zacks: Analysts Expect Arvinas, Inc. (NASDAQ:ARVN) Will Announce Quarterly Sales of $29.11 Million. Posted by admin on Apr 22nd, 2022.
Arvinas reported earnings of ($0.84) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of...
NEW HAVEN, Conn. , Aug. 07, 2019 (GLOBE NEWSWIRE) — Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of ...
Other Companies in New Haven
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $154.8M | 451 | 4% | N/A |
#2 | $206.9M | 496 | 3% | N/A |
#3 | $114.1M | 507 | N/A | N/A |
#4 | $307.6M | 521 | -46% | $443.7M |
#5 | $151.7M | 592 | 3% | N/A |
Arvinas Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-09-27 | $15.0M | A | Article | |
| 2015-10-22 | $41.6M | B | RA Capital Management | Article |
| 2018-04-05 | $55.0M | C | Nextech Invest | Article |